There are currently no approved treatments for systemic<unk> . The current standard of care includes treatments for the underlying inflammatory disease with anti-inflammatory drugs, immunosuppressive agents or biologics.<unk>  patients are also receiving treatments to slow down the decline of their renal function, such as angiotensin II receptor blockers or angiotensin converting enzyme inhibitors.
AA amyloidosis
AL amyloidosis
Secondary systemic amyloidosis
Familial renal amyloidosis
Monoclonal gammopathy of undetermined significance
LECT2 amyloidosis
Organ-limited amyloidosis
Monoclonal gammopathy of renal significance